L Gutierrez-Sainz1, P Cruz2, S Martinez-Recio2, O Higuera2, M I Esteban-Rodriguez3,4, F Arias-Lotto3, R A Gonzalez5, J De Castro-Carpeño2,4,6. 1. Medical Oncology Department, Hospital Universitario La Paz, IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain. laura.gutierrezsainz@gmail.com. 2. Medical Oncology Department, Hospital Universitario La Paz, IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain. 3. Pathology Department, Hospital Universitario La Paz, Madrid, Spain. 4. Translational Oncology Group, IdiPAZ, Madrid, Spain. 5. De La Salle Medical and Health Sciences Institute, Dasmariñas, Philippines. 6. Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, Spain.
Abstract
BACKGROUND: Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor, with a poor prognosis. MPM needs to find prognostic factors of survival. We provided the management of patients with MPM and sought to determine whether pre-treatment levels of derived neutrophil-to-lymphocyte ratio (dNLR) as well as PD-L1 expression were reliable prognostic factors of survival. METHODS: We conducted a single-institution retrospective study, including all patients with MPM treated at La Paz University Hospital between December 2009 and March 2018. Baseline disease, demographics, clinical data, treatment characteristics and complete blood cell counts were collected. We examined dNLR at baseline and data for PD-L1 expression were analyzed in tumor cells by immunohistochemistry. RESULTS: We included 25 patients. The median overall survival (OS) was 15.7 months (95% CI 11.3-20.0). 5 patients had a dNLR greater than 3 (20%). Patients with a dNLR greater than 3 had shorter median OS (8.5 months), than patients with a dNLR less than 3 (17.0 months), with statistically significant differences (p = 0.038). Ten patients (40%) had positive PD-L1 expression (≥ 1%). Patients with positive PD-L1 expression had shorter median OS (8.5 months) than patients with negative PDL1 expression (15.7 months), but without statistically significant association (p = 0.319). CONCLUSION: The survival data obtained in our sample are consistent with those previously reported. Pretreatment levels of dNLR greater than 3 and positive PD-L1 expression could be significant prognostic factors for poor survival in patients with MPM. Further and prospective studies are needed to explore this relationship and to derive definitive conclusions.
BACKGROUND: Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor, with a poor prognosis. MPM needs to find prognostic factors of survival. We provided the management of patients with MPM and sought to determine whether pre-treatment levels of derived neutrophil-to-lymphocyte ratio (dNLR) as well as PD-L1 expression were reliable prognostic factors of survival. METHODS: We conducted a single-institution retrospective study, including all patients with MPM treated at La Paz University Hospital between December 2009 and March 2018. Baseline disease, demographics, clinical data, treatment characteristics and complete blood cell counts were collected. We examined dNLR at baseline and data for PD-L1 expression were analyzed in tumor cells by immunohistochemistry. RESULTS: We included 25 patients. The median overall survival (OS) was 15.7 months (95% CI 11.3-20.0). 5 patients had a dNLR greater than 3 (20%). Patients with a dNLR greater than 3 had shorter median OS (8.5 months), than patients with a dNLR less than 3 (17.0 months), with statistically significant differences (p = 0.038). Ten patients (40%) had positive PD-L1 expression (≥ 1%). Patients with positive PD-L1 expression had shorter median OS (8.5 months) than patients with negative PDL1 expression (15.7 months), but without statistically significant association (p = 0.319). CONCLUSION: The survival data obtained in our sample are consistent with those previously reported. Pretreatment levels of dNLR greater than 3 and positive PD-L1 expression could be significant prognostic factors for poor survival in patients with MPM. Further and prospective studies are needed to explore this relationship and to derive definitive conclusions.
Authors: Vasiliki Panou; Meghana Gadiraju; Arthur Wolin; Caroline M Weipert; Emily Skarda; Aliya N Husain; Jyoti D Patel; Buerkley Rose; Shannon R Zhang; Madison Weatherly; Viswateja Nelakuditi; Amy Knight Johnson; Maria Helgeson; David Fischer; Arpita Desai; Nanna Sulai; Lauren Ritterhouse; Oluf D Røe; Kiran K Turaga; Dezheng Huo; Jeremy Segal; Sabah Kadri; Zejuan Li; Hedy L Kindler; Jane E Churpek Journal: J Clin Oncol Date: 2018-08-16 Impact factor: 44.544
Authors: William D Travis; Elisabeth Brambilla; Andrew G Nicholson; Yasushi Yatabe; John H M Austin; Mary Beth Beasley; Lucian R Chirieac; Sanja Dacic; Edwina Duhig; Douglas B Flieder; Kim Geisinger; Fred R Hirsch; Yuichi Ishikawa; Keith M Kerr; Masayuki Noguchi; Giuseppe Pelosi; Charles A Powell; Ming Sound Tsao; Ignacio Wistuba Journal: J Thorac Oncol Date: 2015-09 Impact factor: 15.609
Authors: Nicholas J Vogelzang; James J Rusthoven; James Symanowski; Claude Denham; E Kaukel; Pierre Ruffie; Ulrich Gatzemeier; Michael Boyer; Salih Emri; Christian Manegold; Clet Niyikiza; Paolo Paoletti Journal: J Clin Oncol Date: 2003-07-15 Impact factor: 44.544
Authors: S Popat; A Curioni-Fontecedro; U Dafni; R Shah; M O'Brien; A Pope; P Fisher; J Spicer; A Roy; D Gilligan; O Gautschi; E Nadal; W D Janthur; R López Castro; R García Campelo; S Rusakiewicz; I Letovanec; V Polydoropoulou; H Roschitzki-Voser; B Ruepp; A Gasca-Ruchti; S Peters; R A Stahel Journal: Ann Oncol Date: 2020-09-22 Impact factor: 32.976
Authors: E Nadal; J de Castro-Carpeño; J Bosch-Barrera; S Cedrés; J Coves; R García-Campelo; M Guirado; R López-Castro; A L Ortega; D Vicente Journal: Clin Transl Oncol Date: 2021-02-04 Impact factor: 3.340